This article is more than 5 years old. Information may no longer be current.

Zyoptix reduces higher-order aberrations, study finds

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NICE, France — Bausch & Lomb's Zyoptix custom ablation system for myopia decreases higher-order aberrations from preoperative levels in some patients, according to a presentation here.

Stephen Slade, MD, discussed early results from a multicenter U.S. trial of the Bausch & Lomb wavefront-guided ablation system here at the European Society of Cataract and Refractive Surgeons meeting.

In the study, 340 myopic eyes were bilaterally treated with Zyoptix. Sixty-one of the eyes had greater than 5 D of myopia.

Postoperatively, at 1 month, 69.7% of patients had uncorrected visual acuity (UCVA) of 20/16 or better, 91.5% had UCVA of 20/20 or better, and 99.4% had UCVA of 20/40 or better, Dr. Slade said. For refraction, 87.5% were within 0.5 D and 95.7% were within 0.75 D, he said.

Results for the first 300 patients indicated 65% showed a decrease in third-order aberrations from preoperative values, Dr. Slade said. "The occurrence of higher-order aberrations was not linked with the level of myopia," he said.